国际标准期刊号: 2381-8727

国际炎症、癌症和综合治疗杂志

开放获取

我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

抽象的

The History of Low Dose Medicine Research Review of Preclinical and Clinical Studies with Low Dose SKA Cytokines Since 2009

Fioranelli M and Roccia MG

Since the second half of the 80s the development of the Psycho-Neuro-Endocrine-Immunology concepts resulted in a change of perspective, from a separatist point of view to an unifying one, relating to the interpretation of the biological functions of the body. A key point was the recognition of the importance of continuous cross-talk between cells, organs and systems in both physiological and pathological conditions based on the fine regulation of the levels of a large number of messenger molecules. Interpreting the pathological phenomenon as an imbalance in intercellular signaling, the administration of low physiological doses of messenger molecules (which act as homeostatic modulating agents) can be considered an intriguing and innovative approach in order to restore the correct intracellular signaling and consequently to restore healthy conditions; these concepts are the milestones of Low Dose Medicine. Five years of scientific research in the field of Low Dose Medicine demonstrated the validity of the conceptual approach and efficacy and safety of the therapeutic intervention based on the oral administration of low doses of activated messenger molecules. This review summarize for the first time the Low Dose Medicine scientific studies published since 2009 and gives a comprehensive overview of the basic and clinical research methodological approaches and results, highlighting the effectiveness of the experimental and clinical use of low dose activated messenger molecules.

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证。